[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vasoplegic-shock\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vasoplegic-shock":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100644555","phase-4-angiotensin-ii-for-post-cardiac-surgery-vasoplegia-angiiv-100644555",false,"NCT07671365","Angiotensin II for Post Cardiac Surgery Vasoplegia (ANGII_V)","ANGII_V","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n  1. Provision of signed and dated informed consent form\n  2. Stated willingness to comply with all study procedures and availability for the duration of the study\n  3. Male or female, aged 18 or over\n  4. Exhibiting vasoplegia or vasoplegic shock following surgeries involving cardiopulmonary bypass\n  5. MAP below results below 65mmHg\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Current use of angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs)\n  2. Presence of treatment with high-dose glucocorticoids\n  3. Pregnancy or lactation\n  4. Known allergic reactions to components of the Giapreza, \\\u003Cspecify components\u002Fallergens\\>\n  5. Febrile illness within \\\u003Cspecify time frame\\>\n  6. Treatment with another investigational drug or other intervention within \\\u003Cspecify time frame\\>\n  7. Current smoker or tobacco use within \\\u003Cspecify timeframe\\>\n  8. Currently receiving VA ECMO for cardiogenic shock\n  9. Experiencing uncontrolled hemorrhage\n  10. Presenting with burns over 20% or more of body, acute coronary syndrome, bronchial spasms, liver failure, mesenteric ischemia, abdominal aortic aneurysm, or an absolute neutrophil count less than 1000 cubic millimeters","ALL","18 Years","94 Years",{"count":20,"type":21},329,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this study is to conduct a prospective trial implementing a modified version of the Emory Protocol for administering ANG II to patients with post cardiac bypass vasoplegia. The main questions we aim to answer are: 1.) does administration of improve mortality, 2.) does the administration of Ang II using the modified protocol shorten the time needed to reach optimal MAP, 3.) does the administration of Ang II using the modified protocol shorten length of stay in the ICU and hospital? Researchers will compare outcomes from the interventional group to historical controls who did not receive Ang II using the modified protocol.",[27,28,29],"Vasoplegic Shock","Cardiopulmonary Bypass","Vasoplegia","NOT_YET_RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":21},"2026-07",{"date":38,"type":21},"2030-08",{"name":40,"class":41},"Methodist Healthcare System of San Antonio","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":5},"100503328","differential-regulation-of-raas-axis-in-patients-undergoing-cardiac-surgery-100503328","NCT05833828","Differential Regulation of RAAS-axis in Patients Undergoing Cardiac Surgery","Differences in Plasma Concentration of RAAS-axis Hormones in Patients Undergoing Cardiac Surgery With or Without Cardiopulmonary Bypass","RAAS-HLM","Inclusion Criteria:\n\n1. adult patients undergoing on- or off-pump coronary artery bypass graft surgery\n2. written informed consent\n\nExclusion Criteria:\n\n1. emergency surgery in the context of acute coronary syndrome\n2. ACE-inhibitor or Angiotensin 1 (AT1)-receptor-blocker intake that was not paused on the day of surgery\n3. Chronic kidney disease with estimated glomerular filtration rate (eGFR)\\\u003C30ml\u002Fmin\u002F1.73m²\n4. Severe structural lung disease (asbestosis, silicosis, severe sarcoidosis, tuberculosis, severe emphysema, chronic obstructive pulmonary disease (COPD) Gold 3-4, lung fibrosis)\n5. Chronic pulmonary hypertension\n6. Pregnancy or breastfeeding\n7. Persons with any kind of dependency on the investigator or employed by the institution responsible or investigator\n8. Persons held in an institution by legal or official order",{"count":51,"type":21},40,"OBSERVATIONAL","This study investigates the question of whether there are differences in the plasma concentration of hormones of the RAAS-axis between patients undergoing on-pump cardiac surgery and those receiving off-pump surgery",[29,27],[56,57,58,59],"vasoplegia","vasoplegic shock","cardiopulmonary bypass","cardiac surgery","RECRUITING","2024-12-06",{"date":63,"type":34},"2024-12-12",{"date":65,"type":34},"2023-08-24",{"date":67,"type":21},"2025-08",{"name":69,"class":41},"Universität Münster"]